Nuo Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Jul 31, 2025 and accepted by EDGAR at Jul 31, 2025, 13:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $700.2k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $1.2m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $159.3k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2025-01-01 to 2025-06-30 | $280.4k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2025-04-01 to 2025-06-30 | $540.9k | us-gaap:GrossProfit |
| Gross profit | 6 months2025-01-01 to 2025-06-30 | $904.2k | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2025-04-01 to 2025-06-30 | $1.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2025-01-01 to 2025-06-30 | $2.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$652.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$649.7k | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$1.4m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | $264.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-01-01 to 2025-06-30 | $231.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-06-30 | $316.4k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $853.3k | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $1.4m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $999.0k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $2.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | −$824.6k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-25-024043. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.